Pediatric Epilepsy Study

Completed · Phase 3

Conditions studied: Epilepsy

In brief

This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as monotherapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.

Key facts

Study ID

NCT00050947

Run by

Novartis Pharmaceuticals

People needed

94

Starts

2002-07-01

Expected to finish

2004-02-01

Last updated by the study team

2011-11-23

Who can join

Age: 0 and older, up to 16. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Mobile, Alabama, United States
• Study site — Madera, California, United States
• Study site — Orange, California, United States
• Study site — Denver, Colorado, United States
• Study site — Miami, Florida, United States
• Study site — Tampa, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Ann Arbor, Michigan, United States
• Study site — Duluth, Minnesota, United States
• Study site — Saint Paul, Minnesota, United States
• Study site — Chesterfields, Missouri, United States
• Study site — St Louis, Missouri, United States
• Study site — Buffalo, New York, United States
• Study site — New York, New York, United States
• Study site — Raleigh, North Carolina, United States
• Study site — Akron, Ohio, United States
• Study site — Cincinnati, Ohio, United States
• Study site — Cleveland, Ohio, United States
• Study site — Portland, Oregon, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — Pittsburgh, Pennsylvania, United States
• Study site — Spartenberg, South Carolina, United States
• Study site — Fort Worth, Texas, United States
• Study site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.